风湿骨痛胶囊治疗活动性强直性脊柱炎的4周随机双盲双模拟对照试验
本研究为4周随机、双盲、双模拟对照试验,纳入180例活动性强直性脊柱炎患者,比较风湿骨痛胶囊联合艾瑞昔布、单用风湿骨痛胶囊与单用艾瑞昔布三组疗效。结果显示三组ASAS20应答率无显著差异,但联合组与单药组在ASDAS-CRP等指标上有改善,且风湿骨痛胶囊胃肠道不良反应发生率较低。
要点
- 风湿骨痛胶囊单用或联合NSAIDs可降低活动性强直性脊柱炎疾病活动度。
- 4周ASAS20应答率三组间无显著差异(P>0.05)。
- 风湿骨痛胶囊组胃肠道不良事件发生率(1.9%)低于艾瑞昔布组(15.7%)。
核心结论
- 风湿骨痛胶囊单用或联合NSAIDs治疗4周对活动性强直性脊柱炎有降低疾病活动度的疗效,且胃肠道耐受性良好。
研究设计与样本
- 随机、对照、双盲、双模拟试验,纳入180例活动性强直性脊柱炎患者,按1:1:1随机分为联合组、风湿骨痛胶囊组和艾瑞昔布组,治疗4周。
- 活动性AS定义:BASDAI≥4或ASDAS-CRP≥2.1。
- 159例(88.3%)完成4周治疗。
主要发现
- 第4周ASAS20应答率:艾瑞昔布组27.5%,联合组37.0%(P>0.05),风湿骨痛胶囊组37.0%(P>0.05)。
- 与艾瑞昔布组相比,联合组ASDAS-CRP和PTGA改善更显著,风湿骨痛胶囊组ASDAS-CRP改善更显著。
- 胃肠道不良事件发生率:艾瑞昔布组15.7%,显著高于风湿骨痛胶囊组1.9%,与联合组7.4%无显著差异。
关键数值与推荐
- 主要终点:第4周ASAS20应答率。
- 次要终点包括ASDAS-CRP、BASDAI、BASFI、BASMI、PGTA和安全性。
- 活动性AS入组标准:BASDAI≥4或ASDAS-CRP≥2.1。
临床怎么用
- 风湿骨痛胶囊可作为活动性强直性脊柱炎的治疗选择之一,尤其关注胃肠道耐受性较差的患者。
- 联合NSAIDs可能改善ASDAS-CRP和患者整体评估,但需结合个体情况。
局限性
- 治疗周期仅4周,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Fengshi Gutong Capsule (FSGTC) is a traditional Chinese herbal medicine that is composed of seven herbs. It has been widely used for the treatment of joint pain in China. However, the clinical evidence supporting its use in patients with ankylosing spondylitis (AS) is lacking. AIM OF THE STUDY: This study aims to explore the efficacy and safety of FSGTC in the treatment of AS. MATERIALS AND METHODS: This randomized, controlled, double-blinded, double-dummy trial enrolled patients with active AS defined as Bath Ankylosing Spondylitis Disease ActivityIndex (BASDAI) ≥ 4 or Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) ≥ 2.1. Eligible patients were randomized (1:1:1) into combination group (FSGTC plus imrecoxib), FSGTC group (FSGTC plus imrecoxib placebo) or imrecoxib group (imrecoxib plus FSGTC placebo) over a 4-week treatment. The primary endpoint was the composite outcome measure of the Assessment in Ankylosing Spondylitis 20% (ASAS20) response at week 4. The secondary endpoints included ASDAS-CRP, BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), patient's global assessment of disease activity (PGTA) and safety. RESULTS: Of the 180 randomized patients, 159 patients (88.3%) completed the 4-week treatment. ASAS20 response rate at week 4 was achieved by 27.5% in imrecoxib group, compared with 37.0% in combination group (P > 0.05) and 37.0% in FSGTC group (P > 0.05). In comparison to imrecoxib group, there were significantly greater improvements of ASDAS-CRP and PTGA in combination group and greater improvement of ASDAS-CRP in FSGTC group while the rest of the secondary endpoints shown similar improvement. The incidence of gastrointestinal adverse events in imrecoxib group (15.7%) was significantly higher than that of FSGTC group (1.9%) and without a significant difference to combination group (7.4%). CONCLUSION: FSGTC alone or combined with NSAIDs has therapeutic efficacy in decreasing disease activity of active AS patients and with good gastrointestinal tolerability after 4-week of treatment.
引用
- Xie Y, Tu L, Zhang Y, et al. Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial. J Ethnopharmacol. 2021. PMID: 34634368. doi:10.1016/j.jep.2021.114731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。